The envelope glycoprotein complex (Env) is responsible for entry of the human
immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and …

Entry of human immunodeficiency virus type 1 (HIV-1) into cells is mediated by attachment of
the envelope glycoproteins, gp120 and gp41, to the CD4 receptor and a chemokine receptor …

The HIV gp41 N-trimer pocket region is an ideal viral target because it is extracellular, highly
conserved, and essential for viral entry. Here, we report on the design of a pocket-specific d …

T20 (generic name: Enfuvirtide, brand name: Fuzeon) is the only FDA-approved HIV fusion
inhibitor that is being used for treatment of HIV/AIDS patients who have failed to respond to …

Human immunodeficiency virus type 1 (HIV-1) entry into the host cell involves a cascade of
events and currently represents one of most attractive targets in the search for new antiviral …

Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion
inhibitor that can irreversibly conjugate to serum albumin. Previous studies demonstrated its …

Sifuvirtide (SFT) is an electrostatically constrained α-helical peptide fusion inhibitor showing
potent anti-HIV activity, good safety, and pharmacokinetic profiles, and it is currently under …

ABSTRACT HIV-1 entry into target cells requires the fusion of viral and cellular membranes.
This process is an attractive target for therapeutic intervention, and a first-generation fusion …

Human immunodeficiency virus (HIV)-1 infection is initiated by the binding of gp120
envelope glyco-protein to its cell receptor (CD4) and a coreceptor (CXCR4 or CCR5) …

Peptides based on the second heptad repeat (HR2) of viral class I fusion proteins are
effective inhibitors of virus entry. One such fusion inhibitor has been approved for treatment …